Oncorus, Inc. (ONCR)
|Net Income (ttm)||n/a|
|Trading Day||May 13|
|Day's Range||14.24 - 15.14|
|52-Week Range||11.50 - 37.86|
-- Enrollment continues in Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate ONCR-177; initial interim data expected in 2H'21 -- -- Company plans to nomi...
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.
These are 7 of the best swing trade stocks on the market right now, but you need to have a strategy and rules in order to be safe. The post 7 of the Best Swing Trade Stocks Available Right Now appeared ...
Oncorus Inc (NASDAQ: ONCR) prices of its underwritten public offering of 3 million common shares at $19 per share, raising $57 million in gross proceeds. The offer price represents a discount of 9% on t...
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to tran...
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to tran...
Oncorus Inc.'s share price has risen by over 120% in about three months of listing. ONCR's novel technology is still a reason to consider the stock as an investment in emerging biopharmaceutical, but th...
Oncorus Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical St...
-- Preclinical findings show that ONCR-177's systemic antitumor immunity is driven by its five complementary immunomodulatory transgene payloads and retention of γ 34.5 -- -- Complete and durable tumor...
-- 88,000 square foot state-of-the-art facility will support Oncorus' advancing, multi-product pipeline of intratumorally and intravenously administered viral immunotherapies –
Oncorus to Participate in Fireside Chats at Upcoming Piper Sandler Annual Healthcare Conference and Evercore ISI Heal...
CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced today ...
-- Received $98.4 million in aggregate gross proceeds in October from initial public offering -- -- Initiated Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the treatment of...
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outc...
CAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc., a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer...
Oncorus Finalizes $87 Million U.S. IPO Effort
Biotech Oncorus Inc. set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $14 to $16 each.
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca ... [Read more...]
|IPO Date |
Oct 2, 2020
|Stock Exchange |
|Ticker Symbol |
According to 3 analysts, the average rating for Oncorus stock is "Strong Buy." The 12-month stock price forecast is 37.75, which is an increase of 160.88% from the latest price.